Article Text

Download PDFPDF
Oral anticoagulants and liver injury: the threat of uncontrolled confounding
  1. Alvaro Alonso1,
  2. Richard F MacLehose2,
  3. Lin Yee Chen2,
  4. Lindsay G S Bengtson3,
  5. Alanna M Chamberlain4,
  6. Faye L Norby2,
  7. Pamela L Lutsey2
  1. 1 Department of Epidemiology, Emory University, Atlanta, Georgia, USA
  2. 2 Division of Epidemiology and Community Health and Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota, USA
  3. 3 Health Economics and Outcomes Research, Life Sciences, Optum, Eden Prairie, Minnesota, USA
  4. 4 Mayo Clinic, Rochester, Minnesota, USA
  1. Correspondence to Dr Alvaro Alonso, Emory University, Atlanta, Georgia, USA; alvaro.alonso{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The Authors’ reply: We value the comments from Drs De Ponti and Raschi about our manuscript reporting the association of oral anticoagulation initiation with the risk of hospitalisation for liver injury1 As they summarise in their letter,2 we showed that among patients with non-valvular atrial fibrillation (AF) initiating oral anticoagulation, the risk of liver injury hospitalisation was highest among those starting warfarin and lowest for dabigatran. Our findings are consistent with those from the large phase …

View Full Text


  • Funding Grants R01HL122200 and R01HL131579 from the National, Heart, Lung and Blood Institute and 16EIA26410001 from the American Heart Association.

  • Competing interests LGSB is an employee of Optum.

  • Provenance and peer review Not commissioned; internally peer reviewed.